Prelude Therapeutics

We announced today that we are participating in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2. Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will share their insight during a fireside chat at 11:30 a.m. ET on Monday. See our press release for details. https://lnkd.in/eHvyENad

We announced financial results for the third quarter of 2024 yesterday and shared updates?on our clinical development pipeline and other corporate milestones. Highlights include ... ?? Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, our first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept. ?? Initiated a Phase 1 trial for PRT7732, our first-in-class oral SMARCA2 degrader in patients with SMARCA4-mutated cancers. ?? Shared first preclinical data from our next generation degrader antibody conjugate (Precision ADC) platform. ?? Will present interim phase 1 clinical data for our potentially best-in-class CDK9 inhibitor, PRT2527, in hematological malignancies at the American Society of Hematology Annual Meeting in December. See our press release for more details. https://lnkd.in/eueEx-Xs

At this week's 36th EORTC-NCI-AACR Symposium in Barcelona, Prelude shared new data in a plenary session from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class, highly selective SMARCA2 degrader designed to treat cancer patients with a SMARCA4 mutation. “We, along with our study investigators, are encouraged by the promising activity shown to date by PRT3789 in this novel first-in-class mechanism for patients who have limited treatment options,” says Jane Huang, M.D., President and Chief Medical Officer of Prelude. “We look forward to further characterizing and understanding the full potential of PRT3789 through ongoing monotherapy dose escalation and in combination studies with both docetaxel and pembrolizumab.” Prelude also provided two poster presentations from our SMARCA Degrader portfolio, including safety data from a combination study of PRT3789 and docetaxel, as well as first preclinical proof-of-concept data from our precision antibody drug conjugate program deploying a novel SMARCA2/4 dual degrader payload. See all the details in today's press release. https://lnkd.in/edX4KqXN

Prelude is heading to the 36th EORTC-NCI-AACR Symposium later this month in Spain, where we're slated to present three abstracts regarding our SMARCA degrader programs. “We are delighted to have this opportunity to share additional information from our SMARCA degrader programs to the scientific and medical communities as we continue to progress both the clinical and preclinical development of these novel first-in-class approaches for patients with high unmet needs,” says CEO Kris Vaddi, Ph.D. ENA attracts an international audience of academics, scientists and pharmaceutical industry leaders and features discussions on the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology. See our press release for more details: https://lnkd.in/gJc8YdvG

Prelude is heading to the 36th EORTC-NCI-AACR Symposium later this month in Spain, where we're slated to present three abstracts regarding our SMARCA degrader programs. “We are delighted to have this opportunity to share additional information from our SMARCA degrader programs to the scientific and medical communities as we continue to progress both the clinical and preclinical development of these novel first-in-class approaches for patients with high unmet needs,” says CEO Kris Vaddi, Ph.D. ENA attracts an international audience of academics, scientists and pharmaceutical industry leaders and features discussions on the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology. See our press release for more details: https://lnkd.in/gJc8YdvG

We're excited to announce that our Chief Business Officer Sean Brusky will be speaking at the ASAP BioPharma 2024 Conference in November. Sean will team up with our partner AbCellera to discuss the work we're doing together to develop first-in-class precision antibody drug conjugates (ADCs) to treat patients with cancer. Prelude and AbCellera joined forces in November 2023, combining our expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera’s antibody discovery and development engine. Register now at asapbiopharma.org. #precisiononcology #DEBio #cancerresearch #asapBioPharma #NetworkingEvent

Today, we announced that our SMARCA2 degrader PRT3789 has demonstrated promising interim clinical data in an ongoing Phase 1 trial. At doses studied to date, PRT3789 was generally well-tolerated and showed encouraging signs of anti-tumor activity in patients with SMARCA4-mutated non-small cell lung cancer and esophageal cancer. “We are encouraged by the early clinical activity and emerging safety profile observed to date with PRT3789,” stated Jane Huang, M.D., President and Chief Medical Officer of Prelude. “These data represent initial proof of concept that selective SMARCA2 degradation can yield antitumor activity in certain SMARCA4-mutated cancers.” We presented the data today at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. See our press release for full details. https://lnkd.in/eFhEHfYn

This week, we'll share our initial clinical data from the Phase 1 study of our highly selective SMARCA2 degrader, PRT3789, via an oral presentation at the Society of Medical Oncology (ESMO) Congress 2024 in Spain. Our abstract, "First Clinical Results from a Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation" is now published on the ESMO 2024 website. See our press release for details: https://lnkd.in/eS9bec9v "We are excited for the opportunity to share the first ever clinical data of a novel, highly-selective SMARCA2 degrader," says Jane Huang, M.D., President and Chief Medical Officer. "Patients whose cancer has a SMARCA4 mutation have limited treatment options and generally very aggressive disease. Although PRT3789 as a first-in-class molecule targeting a novel mechanism is early in its development, we are highly encouraged by the safety profile, target engagement and clinical activity we have seen to date."

Today, we announced financial results for the second quarter of 2024 and shared an update on our clinical development pipeline and other corporate developments. Highlights include ... - Interim Phase 1 data for our first-in-class, highly selective IV SMARCA2 degrader, PRT3789, has been selected for an oral presentation at the European Society for Medical Oncology Congress 2024 in September. - We received investigational new drug (IND) authorization for PRT7732, our first-in-class oral SMARCA2 degrader. - We announced a clinical collaboration with Merck to evaluate PRT3789 in combination with Merck’s anti-PD-1 therapy KEYTRUDA? in patients with SMARCA4-mutated cancers. - Our potentially best-in-class CDK9 inhibitor, PRT2527, remains on track to report interim Phase 1 data in Q4 2024.? A press release is posted on our website: https://lnkd.in/ePyUU5jf

We are excited to announce our clinical collaboration with Merck to evaluate PRT3789, our investigational, highly selective, first-in-class SMARCA2 degrader, in combination with KEYTRUDA?, Merck’s anti-PD-1 therapy, in patients with SMARCA4-mutated cancers. Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA. ? “Through this collaboration of potentially complementary mechanisms, we may have the potential to positively impact clinical outcomes in patients harboring a SMARCA4 mutation, who have previously been known to have limited treatment options.,” says Jane Huang, M.D., Prelude President and Chief Medical Officer. To read today's press release, visit our website: https://lnkd.in/edfnsFyX